# A Study to Evaluate Efficacy and Safety of Anakinra in the Treatment of Still's Disease (SJIA and AOSD)

> **NCT03265132** · PHASE3 · TERMINATED · sponsor: **Swedish Orphan Biovitrum** · enrollment: 13 (actual)

## Conditions studied

- Still's Disease, Adult-Onset
- Still's Disease, Juvenile-Onset

## Interventions

- **BIOLOGICAL:** anakinra
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03265132
- **Lead sponsor:** Swedish Orphan Biovitrum
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-09-26
- **Primary completion:** 2019-02-13
- **Final completion:** 2019-05-23
- **Target enrollment:** 13 (ACTUAL)
- **Why stopped:** Meeting enrolment target (81 pat) will not be feasible within reasonable time.
- **Last updated:** 2021-06-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03265132

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03265132, "A Study to Evaluate Efficacy and Safety of Anakinra in the Treatment of Still's Disease (SJIA and AOSD)". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03265132. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*